Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo therapy shows promise in small melanoma trial

NCT ID NCT03276832

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 20 times

Summary

This early-phase trial tested the safety and effectiveness of combining two drugs—imiquimod (a cream that stimulates the immune system) and pembrolizumab (an immunotherapy injection)—in 7 patients with advanced melanoma that had spread. The goal was to see if the combination could help the body fight the cancer better. The study focused on side effects, tumor shrinkage, and how long patients lived without the cancer getting worse.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Mayo Clinic in Florida

    Jacksonville, Florida, 32224-9980, United States

Conditions

Explore the condition pages connected to this study.